KALA BIO INC

Kala Bio’s mucosal‑drug platform faces a consolidation phase, but upcoming Phase I/II data and potential partnerships could unlock upside beyond its 200‑day average.

Kala Bio’s KALA shares climb 0.53 % to $0.19 amid a biotech downturn, with insights into peers and Nuburu’s Tekne acquisition shaping future prospects.

Kala Bio slides to $0.19, a 66% fall as investors doubt its mucosal drug‑delivery promise – a cautionary biotech tale of high hopes vs. execution.